Published in Parkinsonism Relat Disord on December 06, 2008
History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology (2009) 2.01
Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med (2012) 1.30
Optical coherence tomography in parkinsonian syndromes. PLoS One (2012) 1.24
Recent developments in multiple system atrophy. J Neurol (2009) 1.00
Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractography. BMC Neurol (2011) 0.92
Patterns of focal gray matter atrophy are associated with bradykinesia and gait disturbances in older adults. J Gerontol A Biol Sci Med Sci (2012) 0.92
Putaminal hypointensity in the parkinsonian variant of multiple system atrophy: simple visual assessment using susceptibility-weighted imaging. J Mov Disord (2011) 0.79
Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes. J Neurol (2015) 0.75
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Ambulatory monitoring of freezing of gait in Parkinson's disease. J Neurosci Methods (2007) 1.82
Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med (2011) 1.57
Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med (2011) 1.53
Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet (2011) 1.27
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord (2004) 1.26
Long-term monitoring of gait in Parkinson's disease. Gait Posture (2006) 1.25
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord (2009) 1.19
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet (2004) 1.18
Assessment of interrater and intrarater reliability of the Fahn-Tolosa-Marin Tremor Rating Scale in essential tremor. Mov Disord (2007) 1.17
Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol (2007) 1.14
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord (2006) 1.12
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther (2012) 1.11
Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord (2008) 1.02
Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol (2010) 0.99
Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res (2007) 0.98
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord (2010) 0.98
Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs (2008) 0.97
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol (2003) 0.95
Tetrabenazine for hyperglycemic-induced hemichorea-hemiballismus. Mov Disord (2006) 0.95
Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study. J Neurol Sci (2009) 0.94
Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol (2009) 0.94
A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord (2006) 0.93
Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc (2013) 0.92
Family-based and population-based association studies validate PTPRD as a risk factor for restless legs syndrome. Mov Disord (2011) 0.91
Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery (2003) 0.91
Locomotor response to levodopa in fluctuating Parkinson's disease. Exp Brain Res (2007) 0.88
Benefits and risks of pharmacological treatments for essential tremor. Drug Saf (2003) 0.88
Stereotypies as a manifestation of acute hyperglycemia without ketosis. J Neurol Sci (2011) 0.86
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol (2006) 0.86
Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord (2012) 0.85
Thalamic deep brain stimulation for orthostatic tremor. Tremor Other Hyperkinet Mov (N Y) (2011) 0.84
G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord (2007) 0.83
Pharmacological management of essential tremor. Drugs (2010) 0.83
Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord (2009) 0.83
Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord (2010) 0.82
The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord (2010) 0.81
The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model. Sleep Med (2010) 0.79
Placebo response in Parkinson trials using patient diaries: sites do matter. Clin Neuropharmacol (2007) 0.77
Task-specific focal hand dystonia in a professional pistol-shooter. Clin Neurol Neurosurg (2008) 0.76
Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs. J Neurol Sci (2008) 0.76
Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci (2010) 0.76
Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease. Clin Neuropharmacol (2009) 0.76
Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol (2004) 0.76
Does idiopathic restless legs syndrome delay onset and reduce severity of Parkinson's disease: a pilot study. Int J Neurosci (2014) 0.76
Dextromethorphan/quinidine for chorea: an open-label assessment. Clin Neuropharmacol (2012) 0.76
A pilot study: Microlesion effects and tremor outcome in the ventrointermediate deep brain stimulation (VIM-DBS). Clin Neurol Neurosurg (2010) 0.76
Animal studies in restless legs syndrome. Mov Disord (2007) 0.75
Levodopa-induced dyskinesias in spinocerebellar ataxia type 2. Arch Neurol (2010) 0.75
Effect of tetrabenazine use on restless legs syndrome. Sleep Med (2010) 0.75